Huadong Medicine’s Partner Arcutis Gets FDA Nod for Roflumilast Cream
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, announced that its co-development partner...
Mindray Bio-Medical Partners with Nanjing Municipal Government to Boost Healthcare Innovation
Shenzhen Mindray Bio-Medical Electronics Co., Ltd (SHE: 300760), a leading player in the global medical...
Shenzhen-Based National Biological Manufacturing Innovation Center Breaks Ground
Construction has commenced on a pioneering national biological manufacturing industry innovation center in Shenzhen, marking...
E-Health Now Secures USD 13.8 Million in Series C Financing to Expand AI Medical Services
E-Health Now, a China-based one-stop artificial intelligence (AI)-powered medical health service platform, has reportedly secured...
Merck KGaA Launches First GMP Cell Culture Medium Production Line in China
German pharmaceutical giant Merck KGaA (ETR: MRK) has announced the commencement of commercial manufacturing of...
AusperBio Secures $37 Million in Series A Funding to Advance Hepatitis B Therapy AHB-137
AusperBio, a sino-American biotechnology company specializing in liver therapy development, has reportedly secured USD 37...
Mabwell Bioscience’s 9MW2821 Earns FDA Fast Track Designation for Triple Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...
Shanghai Duoning Biotechnology Partners with BASF SE to Commercialize Medical Materials in China
Shanghai Duoning Biotechnology Co., Ltd, a prominent player in China’s biopharmaceutical industry, has entered into...
NMPA Accepts 3SBio’s Filing for Anemia Treatment SSS06, Potential Game Changer for Dialysis Patients
3SBio Inc. (HKG: 1530), a leading biopharmaceutical company based in China, has announced that the...
Baheal Pharmaceutical Group to Launch Industry Fund Focused on Life Sciences
China’s leading health services and distribution conglomerate, Baheal Pharmaceutical Group, is venturing into the investment...
Huadong Medicine Secures Exclusive Rights to Oral Edaravone Candidate TTYP01 in Major Licensing Deal
Huadong Medicine Co., Ltd (SHE: 000963), a prominent pharmaceutical company in China, has entered into...
Oricell Therapeutics’ GPRC5D-Targeted CAR-T Therapy Earns FDA Fast Track for Multiple Myeloma
Oricell Therapeutics Co., Ltd, a leading biopharmaceutical company based in China, has announced that it...
Legend Biotech’s Shares Leap on Acquisition Rumors; Parent Genscript Biotech Corp. Follows Suit
Chinese biopharmaceutical firm Legend Biotech (NASDAQ: LEGN), a specialist in chimeric antigen receptor (CAR) T-cell...
Oxford Study Clears Semaglutide of Neuro/Psychiatric Risks, Suggests Cognitive and Addiction Benefits
Researchers at the prestigious Oxford University in the UK have unveiled groundbreaking real-world data on...
Simcere Pharmaceutical’s COVID-19 Therapy Xiannuoxin Earns Full Approval in China
Simcere Pharmaceutical Group (HKG: 2096), a biopharmaceutical company based in China, has announced that its...
Beijing Tsingke Biotech Partners with Zhejiang University’s Innovation Center for Nucleic Acid Drug Delivery
Beijing Tsingke Biotech Co., Ltd., a prominent player in the DNA/RNA synthesis domain based in...
Jiangsu Hengrui’s Subsidiary Conducts First Surgical Dosing in Parkinson’s Gene Therapy Clinical Trial
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Medtronic Launches Advanced Signia Stapler in China, Expanding Surgical Capabilities
Medtronic (NYSE: MDT), the US-Irish medical device giant, has announced the launch of its intelligent...
Shanghai Escugen Initiates Phase III Clinical Trial for Breast Cancer Drug Candidate ESG401
Shanghai Escugen, a biopharmaceutical company based in China, has announced the dosing of the first...
Ipsen Strikes Global Licensing Deal with Foreseen Biotechnology for First-in-Class ADC FS001
Ipsen (EPA: IPN; OTCMKTS: IPSEY), a French biopharmaceutical company, has announced a global licensing agreement...